Navigation Links
Ovarian Cancer Prognosis May Depend on Gene Mutations
Date:4/4/2011

MONDAY, April 4 (HealthDay News) -- Ovarian cancer patients with the BRCA2 gene mutation are more likely to survive than those with the BRCA1 mutation or patients without either mutation, a new study finds.

U.S. researchers analyzed 3,531 cases of epithelial ovarian cancer, including 1,178 patients with BRCA1 mutations, 367 with BRCA2 mutations and 1,986 with neither mutation.

Five-year survival rates were 61 percent for those with the BRCA2 mutation, 46 percent for those with the BRCA1 mutation and 36 percent for those with neither mutation, the investigators found.

The study is to be presented Monday at the annual meeting of the American Association for Cancer Research, in Orlando, Fla. The research is considered preliminary until it is published in a peer-reviewed journal.

"There was some previous evidence that women with ovarian cancer who have mutations in the BRCA genes show improved survival compared to non-mutation carriers. Our study clearly shows that this survival difference is real. We also provide the first solid evidence that BRCA1 and BRCA2 mutations don't have the same impact on ovarian cancer survival," Kelly Bolton, a fellow at the U.S. National Cancer Institute, said in an AACR news release.

Further research is needed to find out why BRCA2 mutations are associated with better survival than BRCA1 mutations or no mutations. The mutations may affect a patient's response to chemotherapy, Bolton suggested.

About 1 in 400 to 1 in 800 women are born with either the BRCA1 or BRCA2 mutations, which increase the risk of ovarian and breast cancer. About 5 percent of ovarian cancer patients have BRCA1 or BRCA2 mutations.

More information

The American Cancer Society has more about ovarian cancer.

-- Robert Preidt

SOURCE: American Association for Cancer Research, news release, April 4, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Philanthropic pledge triples funds for TGen ovarian cancer research
2. Ohio State study: Targeted ovarian cancer therapy not cost-effective
3. GPs take more than a month to record ovarian cancer diagnosis in one in 10 cases
4. Nearly 25% of Women With Early Ovarian Cancer Not Given Recommended Biopsies
5. New clinical trial to determine ovarian cancer risks in African-American women
6. Ovarian Cyst Syndrome May Raise Health Risks from Plastics Chemical
7. UH biochemist works to revolutionize ovarian cancer treatment
8. Ovarian cancer advances when genes are silenced
9. Few Lives Saved by Ovarian Cancer Screening: Study
10. Biological diversity of ovarian cancer lessens value of screening
11. Researchers map the way to personalised treatment for ovarian cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Ovarian Cancer Prognosis May Depend on Gene Mutations
(Date:2/10/2016)... NASHVILLE, Tenn. (PRWEB) , ... February 10, 2016 ... ... by the American Academy of Emergency Medicine , an emergency medicine ... of practice management services . , The American Academy of Emergency Medicine, ...
(Date:2/10/2016)... ... February 10, 2016 , ... The Wickman Agency in ... assist the local community. Pledging to select a new beneficiary every 60 days, ... area. Their goal is to bring community awareness to important local causes by ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... 10 ... Brand. There were three leading bottled water brand owners that topped the list as ... enhance connectivity and optimize conversion. The premier brand was Tibet 5100, a top notch ...
(Date:2/10/2016)... ... , ... Dr. Jessica Barron, of Barron Family Dental in Thornton, Colorado ... families in the North Metro Denver area. The new dental practice focuses on comfort ... all in the most relaxing environment. , While some dental visits can create anxiety ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... bring together more than 200 of the country’s top healthcare executives to share ... “The true benefit of the Forum is the provider-centric perspective, experience, expertise and ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... -- Resolve Therapeutics, LLC, a clinical stage biopharmaceutical company ... of lupus and Sjogrens syndrome, today announced the ... in patients with systemic lupus erythematosus (SLE) with ... --> Data from a multicenter ... RSLV-132 in 32 subjects with SLE demonstrate the ...
(Date:2/10/2016)... HILLS, Calif. , Feb. 10, 2016  Rich ... "Company") today announced a 1-for-100 reverse split of its ... the opening of trading on Thursday, February 11, 2016. ... basis under new CUSIP number 76303T308 and temporary ticker ... will commence trading under the ticker symbol (RCHA).  ...
(Date:2/10/2016)... MEMPHIS, Tenn. , Feb. 10, 2016 ... School of Nursing received an in-kind ... of a VeinViewer® Vision vein finder ... donation will help students as they learn ... blood, combining technology with traditional technique. ...
Breaking Medicine Technology: